Senti Bio Receives $8 Million CIRM Grant to Advance Logic-Gated CAR-NK Cell Therapy for AML
Senti Biosciences, Inc., a leader in next-generation cell and gene therapies, has been awarded an $8 million grant by the California Institute for Regenerative Medicine (CIRM). This significant funding will propel the clinical development of SENTI-202, an innovative off-the-shelf CAR-NK cell therapy designed to treat relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML). Pioneering Cell […]
AvenCell’s AVC-201: A New Era in Leukemia Therapy
AvenCell Therapeutics, a leading clinical-stage cell therapy company, has announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA) for AVC-201. AVC-201 is a novel allogeneic CD123-directed switchable CAR-T investigational therapy for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and other CD123 positive hematological malignancies. This therapy is the world’s […]
GT Biopharma and Fate Therapeutics Present Preclinical Data Highlighting Novel Dual Antigen Targeting Approach For The Treatment of AML at ASH 2022
BRISBANE, CALIFORNIA, Dec. 12, 2022 (GLOBE NEWSWIRE) — GT Biopharma, Inc. (NASDAQ: GTBP) today announced the presentation of new preclinical data at the American Society of Hematology’s 64th Annual Meeting (ASH 2022). The presentation highlights the potential of a novel dual antigen targeting approach for the treatment of acute myeloid leukemia (AML) by combining GT […]
Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA
CAMBRIDGE, Mass., June 10, 2022 (GLOBE NEWSWIRE) — Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced successful first of its kind dual editing of CD33 and CLL-1 in human hematopoietic stem cells (HSCs) demonstrating continued progress on its novel approach for the treatment of acute myeloid leukemia (AML). The data […]